We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.35
Bid: 4.20
Ask: 4.50
Change: 0.10 (2.35%)
Spread: 0.30 (7.143%)
Open: 4.25
High: 4.35
Low: 4.25
Prev. Close: 4.25
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Approval of 3AEY in Spain

22 Feb 2016 07:00

RNS Number : 6498P
Eden Research plc
22 February 2016
 

Eden Research Plc

("Eden" or "Company")

 

Approval of 3AEY in Spain

 

Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that is has now received authorisation in Spain for its first product, 3AEY, for use in the prevention and treatment of botrytis in table and wine grapes. 3AEY will be sold in Spain by Eden's partner Sipcam Iberia, S.L. ("Sipcam") under the tradename "ARAW"™. Eden will realise royalties from the sale of ARAW in Spain.

 

This is another significant milestone for Eden which allows the Company to access the third largest wine producer in the world. 3AEY has already been authorised for sale in Kenya, Malta, Greece, Bulgaria and most recently Italy, increasing the geographic footprint of sales in the 2016 growing season. 3AEY is a terpene-based fungicide that specifically targets Botrytis, a widespread fungal disease that causes grey mould on many fruits and vegetables leading to the rapid loss of commercially valuable crops. Botrytis can destroy as much as 30% of a vineyard in a matter of days if vines are left untreated.

 

Sean Smith, Chief Executive Officer of Eden, said: "Approval in Spain represents the clearance of another hurdle in the commercialisation of 3AEY across Southern Europe, which has been eagerly anticipated by Eden, Sipcam and growers alike. Spain is a major producer of high-value fruits and vegetables, including grapes, and it is the third largest wine producer in the world. Sipcam has already initiated pre-marketing efforts and is now able to pursue full product launch for ARAW™ in time for this year's growing season. Sipcam is well-positioned to gain a substantial market share over the next few years, and we will work to support them wherever possible.

 

"Going forward, we will continue to work with Sipcam to support the further development of 3AEY for non-grape crops through the label extension process. Furthermore, we are also working together to explore the potential to develop 3AEY for the treatment of other fungal pathogens on grapes and other high-value fruits and vegetables.

 

"Spain grows a number of other indoor crops which are exported all around the world. The worker safety benefits of using effective, biological products, such as 3AEY, when used in enclosed environments are clear and desirable. This presents Sipcam with the opportunity to sell 3AEY, in due course, for crops other than grapes which will help to derive further value from the investment that both Eden and Sipcam have made to date."

 

 

Eden Research plc

www.edenresearch.com

Sean Smith, Chief Executive Officer

Tel: 01285 359 555

Alex Abrey, Chief Financial Officer

Shore Capital and Corporate Limited

www.shorecap.com

Stephane Auton/Patrick Castle

Tel: 020 7408 4090

Walbrook PR Ltd

Tel: 020 7933 8780 or eden@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

Notes:

 

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

 

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic hydrophobic compounds. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

 

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

 

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

 

The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into licence agreements.

 

In May of 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represents a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company. To illustrate this point, one should note that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.

 

3AEY has already been authorised for sale in Kenya, Malta, Greece, Bulgaria and Italy.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

 

For more information about Eden, please visit: www.edenresearch.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCAKCDBABKDABD
Date   Source Headline
31st Jan 20247:00 amRNSBoard Change
22nd Jan 20247:00 amRNSTrading Update
19th Jan 20243:00 pmRNSHolding(s) in Company
9th Jan 20247:01 amRNSMevalone Approval in the State of California
18th Dec 20237:00 amRNSEcovelexâ„¢2023 Approval in Italy
28th Nov 20237:00 amRNSSmall Cap Virtual Investor Conference
1st Nov 20237:00 amRNSChange of Nominated Adviser and Broker
9th Oct 20234:44 pmRNSHolding(s) in Company
9th Oct 20234:39 pmRNSHolding(s) in Company
9th Oct 202312:46 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSCompletion of Conditional Placing
29th Sep 20237:01 amRNSHalf Yearly Report
29th Sep 20237:00 amRNSCapital Raising Update
31st Aug 20236:25 pmRNSGrant of Awards under Long-Term Incentive Plan
17th Aug 20239:27 amRNSResult of GM and Capital Raising update
16th Aug 20237:00 amRNSFirst Order For Ecovelex
2nd Aug 20233:22 pmRNSResult of Retail Offer
28th Jul 20235:00 pmRNSRetail Offer
28th Jul 20235:00 pmRNSPlacing and Retail Offer
3rd Jul 20237:00 amRNSRegulatory Application for Ecovelex in the UK
30th Jun 20239:17 amRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
15th Jun 20237:00 amRNSAppointment of New Product Distributor – Colombia
9th Jun 20234:29 pmRNSHolding(s) in Company
7th Jun 20237:00 amRNSPublication of Annual Report and Notice of AGM
5th Jun 20234:47 pmRNSHolding(s) in Company
30th May 20237:00 amRNSEden and Corteva seek to bring Ecovelex to market
17th May 20237:00 amRNSExercise of Options
15th May 20237:00 amRNSMevalone authorisation in New Zealand
12th May 20237:00 amRNSRegulatory approvals in California and Florida
5th May 20237:00 amRNSPreliminary results for the year ended 31 Dec 2022
17th Apr 20237:00 amRNSRegulatory authorisation for Mevalone in Poland
23rd Mar 20237:00 amRNSUS State Regulatory Approvals Update
30th Jan 20237:00 amRNSFirst Mevalone authorisation for domestic use
10th Jan 20237:00 amRNSTrading Update
15th Dec 20222:01 pmEQSEden Research signs new Mevalone distribution deal
15th Dec 20227:00 amRNSDistribution Agreement for Mevalone in France
30th Nov 20227:00 amRNSOrganic Certification in Greece
24th Oct 202212:00 pmRNSAIM Rule 17 Notification
3rd Oct 20224:39 pmRNSHolding(s) in Company
30th Sep 20227:00 amRNSEden Half Yearly Report
28th Sep 20228:46 amRNSAppointment of Auditor
27th Sep 20225:08 pmEQSEden granted US EPA regulatory approval
26th Sep 20227:00 amRNSEden granted US EPA regulatory approval
2nd Sep 20227:00 amRNSAppointment of Non-Executive Director
22nd Aug 20227:00 amRNSTrading Update
7th Jul 20227:00 amRNSExercise of Options
29th Jun 202212:18 pmRNSResult of AGM
29th Jun 20227:00 amRNSAGM Statement
8th Jun 20227:12 amRNSNotice of AGM & Publication of Annual Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.